U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Advanced Lung Non-Small Cell Carcinoma

MedGen UID:
1701032
•Concept ID:
C5206378
•
Neoplastic Process

Definition

Lung non-small cell carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment. [from NCI]

Professional guidelines

PubMed

Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: a matter of debate.
Rizzo A
Br J Cancer 2022 Nov;127(8):1381-1382. Epub 2022 Sep 5 doi: 10.1038/s41416-022-01929-w. PMID: 36064585Free PMC Article
Atezolizumab Monotherapy or Plus Chemotherapy in First-Line Treatment for Advanced Non-Small Cell Lung Cancer Patients: A Meta-Analysis.
Li DN, Lu WQ, Yang BW, Zhang LY, Jin B, Wang S, Che XF, Li C, Liu YP, Qu XJ
Front Immunol 2021;12:666909. Epub 2021 Jun 2 doi: 10.3389/fimmu.2021.666909. PMID: 34149702Free PMC Article
Immune checkpoint inhibitors for the management of advanced non-small-cell lung carcinoma: a meta-analysis.
Lai LT, Zhan ZY, Feng M, Li F, Lai LF, Zhong LX
Anticancer Drugs 2020 Jul;31(6):637-645. doi: 10.1097/CAD.0000000000000921. PMID: 32058346

Recent clinical studies

Etiology

Non-small cell lung cancer in China.
Chen P, Liu Y, Wen Y, Zhou C
Cancer Commun (Lond) 2022 Oct;42(10):937-970. Epub 2022 Sep 8 doi: 10.1002/cac2.12359. PMID: 36075878Free PMC Article
Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment.
Duma N, Santana-Davila R, Molina JR
Mayo Clin Proc 2019 Aug;94(8):1623-1640. doi: 10.1016/j.mayocp.2019.01.013. PMID: 31378236
Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer.
Wu SG, Shih JY
Mol Cancer 2018 Feb 19;17(1):38. doi: 10.1186/s12943-018-0777-1. PMID: 29455650Free PMC Article
Non-small-cell lung cancer.
Gridelli C, Rossi A, Carbone DP, Guarize J, Karachaliou N, Mok T, Petrella F, Spaggiari L, Rosell R
Nat Rev Dis Primers 2015 May 21;1:15009. doi: 10.1038/nrdp.2015.9. PMID: 27188576
Lung cancer.
Maghfoor I, Perry MC
Ann Saudi Med 2005 Jan-Feb;25(1):1-12. doi: 10.5144/0256-4947.2005.1. PMID: 15822487Free PMC Article

Diagnosis

Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology.
Riely GJ, Wood DE, Ettinger DS, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, DeCamp M, Desai AP, Dilling TJ, Dowell J, Durm GA, Gettinger S, Grotz TE, Gubens MA, Juloori A, Lackner RP, Lanuti M, Lin J, Loo BW, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Mullikin TC, Ng T, Owen D, Owen DH, Patel SP, Patil T, Polanco PM, Riess J, Shapiro TA, Singh AP, Stevenson J, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory KM, Hang L
J Natl Compr Canc Netw 2024 May;22(4):249-274. doi: 10.6004/jnccn.2204.0023. PMID: 38754467
Non-small cell lung cancer in China.
Chen P, Liu Y, Wen Y, Zhou C
Cancer Commun (Lond) 2022 Oct;42(10):937-970. Epub 2022 Sep 8 doi: 10.1002/cac2.12359. PMID: 36075878Free PMC Article
Lung cancer.
Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS
Lancet 2021 Aug 7;398(10299):535-554. Epub 2021 Jul 21 doi: 10.1016/S0140-6736(21)00312-3. PMID: 34273294
Update 2020: Management of Non-Small Cell Lung Cancer.
Alexander M, Kim SY, Cheng H
Lung 2020 Dec;198(6):897-907. Epub 2020 Nov 11 doi: 10.1007/s00408-020-00407-5. PMID: 33175991Free PMC Article
Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment.
Duma N, Santana-Davila R, Molina JR
Mayo Clin Proc 2019 Aug;94(8):1623-1640. doi: 10.1016/j.mayocp.2019.01.013. PMID: 31378236

Therapy

HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC.
Yu HA, Yang JC, Hayashi H, Goto Y, Felip E, Reck M, Vigliotti M, Dong Q, Cantero F, Fan PD, Kanai M, Sternberg DW, Jänne PA
Future Oncol 2023 Jun;19(19):1319-1329. Epub 2023 May 22 doi: 10.2217/fon-2022-1250. PMID: 37212796
Targeted therapy in advanced non-small cell lung cancer: current advances and future trends.
Majeed U, Manochakian R, Zhao Y, Lou Y
J Hematol Oncol 2021 Jul 8;14(1):108. doi: 10.1186/s13045-021-01121-2. PMID: 34238332Free PMC Article
Emerging therapeutic agents for advanced non-small cell lung cancer.
Chen R, Manochakian R, James L, Azzouqa AG, Shi H, Zhang Y, Zhao Y, Zhou K, Lou Y
J Hematol Oncol 2020 May 24;13(1):58. doi: 10.1186/s13045-020-00881-7. PMID: 32448366Free PMC Article
The biology and management of non-small cell lung cancer.
Herbst RS, Morgensztern D, Boshoff C
Nature 2018 Jan 24;553(7689):446-454. doi: 10.1038/nature25183. PMID: 29364287
Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer.
Nagasaka M, Gadgeel SM
Expert Rev Anticancer Ther 2018 Jan;18(1):63-70. Epub 2017 Nov 26 doi: 10.1080/14737140.2018.1409624. PMID: 29168933Free PMC Article

Prognosis

The Effect of Advances in Lung-Cancer Treatment on Population Mortality.
Howlader N, Forjaz G, Mooradian MJ, Meza R, Kong CY, Cronin KA, Mariotto AB, Lowy DR, Feuer EJ
N Engl J Med 2020 Aug 13;383(7):640-649. doi: 10.1056/NEJMoa1916623. PMID: 32786189Free PMC Article
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
Shaw AT, Solomon BJ, Chiari R, Riely GJ, Besse B, Soo RA, Kao S, Lin CC, Bauer TM, Clancy JS, Thurm H, Martini JF, Peltz G, Abbattista A, Li S, Ou SI
Lancet Oncol 2019 Dec;20(12):1691-1701. Epub 2019 Oct 25 doi: 10.1016/S1470-2045(19)30655-2. PMID: 31669155
Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.
Shaw AT, Riely GJ, Bang YJ, Kim DW, Camidge DR, Solomon BJ, Varella-Garcia M, Iafrate AJ, Shapiro GI, Usari T, Wang SC, Wilner KD, Clark JW, Ou SI
Ann Oncol 2019 Jul 1;30(7):1121-1126. doi: 10.1093/annonc/mdz131. PMID: 30980071Free PMC Article
The biology and management of non-small cell lung cancer.
Herbst RS, Morgensztern D, Boshoff C
Nature 2018 Jan 24;553(7689):446-454. doi: 10.1038/nature25183. PMID: 29364287
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, Escriu C, Peters S; ESMO Guidelines Committee
Ann Oncol 2017 Jul 1;28(suppl_4):iv1-iv21. doi: 10.1093/annonc/mdx222. PMID: 28881918

Clinical prediction guides

New promises and challenges in the treatment of advanced non-small-cell lung cancer.
Meyer ML, Fitzgerald BG, Paz-Ares L, Cappuzzo F, Jänne PA, Peters S, Hirsch FR
Lancet 2024 Aug 24;404(10454):803-822. Epub 2024 Aug 6 doi: 10.1016/S0140-6736(24)01029-8. PMID: 39121882
Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.
Shields MD, Chen K, Dutcher G, Patel I, Pellini B
Int J Mol Sci 2022 Aug 12;23(16) doi: 10.3390/ijms23169006. PMID: 36012272Free PMC Article
Advances in the Treatment of Non-Small Cell Lung Cancer: Immunotherapy.
Patel SA, Weiss J
Clin Chest Med 2020 Jun;41(2):237-247. Epub 2020 Apr 16 doi: 10.1016/j.ccm.2020.02.010. PMID: 32402359
Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment.
Duma N, Santana-Davila R, Molina JR
Mayo Clin Proc 2019 Aug;94(8):1623-1640. doi: 10.1016/j.mayocp.2019.01.013. PMID: 31378236
Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer.
Wu SG, Shih JY
Mol Cancer 2018 Feb 19;17(1):38. doi: 10.1186/s12943-018-0777-1. PMID: 29455650Free PMC Article

Recent systematic reviews

Comparative safety of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced anaplastic lymphoma kinase-mutated non-small cell lung cancer: Systematic review and network meta-analysis.
Luo Y, Zhang Z, Guo X, Tang X, Li S, Gong G, Gao S, Zhang Y, Lin S
Lung Cancer 2023 Oct;184:107319. Epub 2023 Aug 7 doi: 10.1016/j.lungcan.2023.107319. PMID: 37597303
TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC).
Parisi C, Mahjoubi L, Gazzah A, Barlesi F
Cancer Treat Rev 2023 Jul;118:102572. Epub 2023 May 19 doi: 10.1016/j.ctrv.2023.102572. PMID: 37230055
Neoadjuvant immunotherapy for advanced, resectable non-small cell lung cancer: A systematic review and meta-analysis.
Wu Y, Verma V, Gay CM, Chen Y, Liang F, Lin Q, Wang J, Zhang W, Hui Z, Zhao M, Wang J, Chang JY
Cancer 2023 Jul 1;129(13):1969-1985. Epub 2023 Mar 30 doi: 10.1002/cncr.34755. PMID: 36994945
Anti-TIGIT therapies for solid tumors: a systematic review.
Rousseau A, Parisi C, Barlesi F
ESMO Open 2023 Apr;8(2):101184. Epub 2023 Mar 16 doi: 10.1016/j.esmoop.2023.101184. PMID: 36933320Free PMC Article
Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis.
Zhao Y, Liu J, Cai X, Pan Z, Liu J, Yin W, Chen H, Xie Z, Liang H, Wang W, Guo Z, Zhao S, Liang W, He J
BMJ 2019 Oct 7;367:l5460. doi: 10.1136/bmj.l5460. PMID: 31591158Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...